Multisite, retrospective chart review of practice patterns and outcomes in patients with early-stage classical HL at different institutions within the United States Read more
Characterization and treatment of daratumumab-associated infections in patients with multiple myeloma. Read more
Impact of novel salvage regimens in patients with relapsed/refractory primary mediastinal B-cell lymphoma prior to autologous stem cell transplant Read more
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL) Read more
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody Read more
Ph1 T-cell lymphoma study: An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma Read more
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide Read more
Plasmablastic Lymphoma: Changing Outcomes in People Living With and Without HIV and Other Immunosuppressed States in the Era of Modern Antiretroviral Therapy. Read more
